Medical Oncologist
Chronic Myeloid Leukaemia
CML Treatment with TKIs: — Living a Normal Life Span
CML is caused by a single genetic change — the BCR-ABL1 fusion. Targeted therapy in tablet form blocks that change directly. Most patients diagnosed in the chronic phase who take their tablet consistently and attend monitoring appointments now reach a life span close to that of people without cancer.
Medically reviewed by Dr. C. Raghavendra Reddy, Medical Oncologist, MBBS (Gold Medal) · DNB · DM (Medical Oncology, Gold Medal) · Last reviewed August 2026
- One genetic driver — CML is caused by a single abnormal fusion gene, BCR-ABL1, making it highly treatable with drugs designed specifically to block it.
- Tablet, not chemotherapy — TKIs are taken as a daily tablet at home. You do not need an infusion or a hospital stay for each dose.
- Monitoring is central — Regular BCR-ABL1 blood tests — not symptoms — guide every treatment decision your oncologist makes.
- Stopping treatment is a goal — Some patients who sustain a deep molecular response can eventually stop their TKI under close supervision.
17+
Cancer Specialists
on Panel
on Panel
96.9%
Breast Cancer
Survival Rate*
Survival Rate*
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
CML is caused by a single abnormal gene, BCR-ABL1, and targeted therapy in tablet form blocks it directly. Most patients diagnosed in the chronic phase who take their TKI consistently now reach a life span close to that of people without cancer, according to NCCN and ESMO guidance.
How does CML treatment work from diagnosis to long-term care?
Confirm the diagnosis
A full blood count raises the suspicion. BCR-ABL1 PCR — a blood test that quantifies the abnormal gene — and FISH or cytogenetics confirming the Philadelphia chromosome establish the diagnosis with certainty.
Establish your phase
CML is classified as chronic, accelerated, or blast phase. The vast majority of diagnoses happen in the chronic phase. Your phase determines urgency and which drugs are appropriate.
Start a TKI tablet
You begin a tyrosine kinase inhibitor — a daily tablet that blocks the BCR-ABL1 protein. The specific drug is chosen based on your phase, age, cardiovascular history, and risk score.
Test BCR-ABL1 at set milestones
Your BCR-ABL1 level is measured by PCR blood test at regular intervals after starting treatment. These milestones — not symptoms — are how your oncologist knows whether treatment is working.
Adjust if milestones are not met
If your BCR-ABL1 level does not fall as expected, kinase domain mutation sequencing checks whether the gene has developed resistance. A different TKI is then selected based on that result.
Aim for deep molecular response
The goal is to reach and sustain a deep molecular response. For carefully selected patients who hold this level over a sustained period, stopping treatment under close supervision becomes an option.
What do the key terms in your CML reports mean?
- BCR-ABL1
- The abnormal fusion gene — and the protein it produces — that drives CML. All TKIs are designed to block this protein. Your BCR-ABL1 level, reported as a percentage on the international scale, is how response to treatment is measured.
- Philadelphia chromosome
- The chromosomal rearrangement present in over 95% of CML cases, formed by material swapping between chromosomes 9 and 22. It is what creates BCR-ABL1. FISH testing detects it directly.
- Chronic phase
- The earliest and most treatable stage of CML. Most diagnoses happen here, often on a routine blood count before any symptoms appear. TKIs are highly effective in chronic phase.
- Major molecular response (MMR)
- A key response milestone where BCR-ABL1 falls to 0.1% or below on the international scale. Reaching MMR by 12 months is associated with durable long-term control according to NCCN guidelines.
- Deep molecular response (MR4 / MR4.5)
- A level of response deeper than MMR, where BCR-ABL1 is detectable at very low levels or is undetectable. Sustaining deep molecular response for a defined period is required before treatment-free remission can be considered.
- Treatment-free remission (TFR)
- Stopping TKI therapy under close supervision. It is not available to everyone — it requires sustained deep molecular response — but it is a recognised goal of CML treatment according to NCCN and ESMO guidelines.
- Kinase domain mutation
- A change within the BCR-ABL1 gene that reduces how well a TKI can bind and block the protein. Tested when response milestones are missed. The T315I mutation is the most significant because it resists most TKIs except ponatinib and asciminib.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
You do not have to work this out alone
A 45-minute consultation with a specialist who treats this every week.
Which tests decide your treatment, and which drug do you start?
At diagnosis, BCR-ABL1 PCR confirms the disease and gives a baseline level. FISH or cytogenetics confirms the Philadelphia chromosome. These tests are usually done from a blood sample or from the bone marrow biopsy taken at diagnosis.
If your BCR-ABL1 level does not fall as expected at the three-, six-, or twelve-month milestones, kinase domain mutation sequencing is ordered. This identifies specific changes in the BCR-ABL1 gene that reduce the effectiveness of the TKI you are taking. The T315I mutation is the most clinically important — it resists all first- and second-generation TKIs and requires a specific drug in response.
First-generation TKIs have the longest safety record and remain effective for many patients. Second-generation TKIs offer alternatives as first-line therapy or after an inadequate response, and they differ in which mutations they can overcome and in their side effect profiles. Ponatinib and asciminib are reserved for patients with the T315I mutation or those who have not responded adequately to two or more prior TKIs. Your oncologist selects the drug based on your mutation result, your phase, your cardiovascular history, and your other health conditions.
What does long-term TKI treatment feel like day to day?
TKIs are taken as a tablet once or twice daily, at home. You do not come to hospital for each dose. Most people continue working, travelling, and living a routine life during treatment.
The most commonly reported side effects include fluid retention (swelling around the eyes or ankles), nausea, muscle cramps, skin rash, and tiredness. Many of these improve after the first few weeks. Serious effects — such as changes in heart rhythm, fluid around the lungs, or liver enzyme rises — are less common and are detected through regular blood tests before they cause symptoms.
Adherence is the most important factor you directly control. Missing doses consistently is one of the most preventable causes of inadequate response in CML. If a side effect is making it hard to take the tablet, tell your oncologist — dose adjustment or a switch to a better-tolerated TKI is usually an option, and it is far safer than stopping on your own.
Did you know?
Before targeted therapy became available, survival for most patients with CML was measured in a small number of years. NCCN and ESMO guidelines now state that most patients diagnosed in chronic phase on a modern TKI can expect a life span approaching that of the general population.
This transformation happened within one generation of medicine — and it happened because of drugs targeting a single abnormal protein.
Source: NCCN Clinical Practice Guidelines in Oncology: CML; ESMO Clinical Practice Guidelines for CML 2020
Explore 119 more Targeted Therapy Basics, Testing & Your Cancer Type topics
Cancer-Type Specific Targeted Therapy
- CML Treatment with TKIs: Living a Normal Life Span
- Cancer of Unknown Primary: Can Molecular Testing Help?
- GIST Treatment: Why This Cancer Changed Targeted Therapy Forever
- Targeted Therapy for Bile Duct Cancer (Cholangiocarcinoma)
- Targeted Therapy for Bladder and Urothelial Cancer
- Targeted Therapy for Brain Tumours and Glioma
- Targeted Therapy for Breast Cancer: HER2, HR+ and Triple Negative
- Targeted Therapy for CLL and Lymphoma
- Targeted Therapy for Cervical and Endometrial Cancer
- Targeted Therapy for Childhood Cancers
- Targeted Therapy for Colorectal Cancer: RAS, BRAF and HER2
- Targeted Therapy for Head and Neck Cancer
- Targeted Therapy for Kidney Cancer (RCC)
- Targeted Therapy for Liver Cancer (HCC)
- Targeted Therapy for Lung Cancer: Every Mutation and Drug Explained
- Targeted Therapy for Melanoma: BRAF and MEK Inhibitors
- Targeted Therapy for Multiple Myeloma
- Targeted Therapy for Neuroendocrine Tumours
- Targeted Therapy for Ovarian Cancer: PARP Inhibitors and Beyond
- Targeted Therapy for Pancreatic Cancer: Limited but Real Options
- Targeted Therapy for Prostate Cancer
- Targeted Therapy for Sarcoma
- Targeted Therapy for Stomach and Gastroesophageal Cancer
- Targeted Therapy for Thyroid Cancer
- Targeted Therapy in AML: Beyond Standard Chemotherapy
- Tumour-Agnostic Drugs: When the Mutation Matters More Than the Organ
Before You Start - Preparation & Baseline
- 25 Questions to Ask Your Oncologist Before Starting Targeted Therapy
- Before You Start Targeted Therapy: The Complete Preparation Checklist
- Dental Check-Up Before Cancer Treatment: Why It Matters
- Financial Planning Before Starting Long-Term Targeted Therapy
- How Long After Surgery Can You Start Targeted Therapy?
- How to Store Your Targeted Therapy Tablets Correctly
- Setting Up a Dosing Routine You Won't Forget
- Should Targeted Therapy Be Taken With Food or on an Empty Stomach?
- Vaccinations Before and During Cancer Treatment
- What to Expect in Your First Month on Targeted Therapy
- Which Baseline Tests Are Done Before Starting a TKI?
- Which of Your Existing Medicines Must Stop Before Targeted Therapy
- Why You Need an ECHO and ECG Before Certain Cancer Drugs
Biomarker & Molecular Testing
- Can Mutation Testing Be Done on an Old Biopsy Block or Slides?
- Cost of NGS and Mutation Testing in India: 2026 Price Guide
- Do I Need Genetic Testing Before Starting Targeted Therapy?
- Germline vs Somatic Testing: The Difference Nobody Explains Properly
- Getting a Second Opinion on Your Genomic Report
- How Long Do Mutation Test Results Take in India? Realistic Timelines
- How to Read Your Molecular Pathology Report, Line by Line
- IHC, FISH, PCR or NGS: Which Mutation Test Is Right for Your Cancer?
- Is Mutation Testing Worth It If I Can't Afford the Drug?
- Liquid Biopsy vs Tissue Biopsy: Which Test Do You Need?
- My Report Says a Mutation Is 'Actionable': What Does That Mean?
- No Mutation Found in My Report: What Are My Options Now?
- Should I Start Chemotherapy While Waiting for Mutation Results?
- Should You Repeat Molecular Testing After Your Cancer Progresses?
- Single-Gene Test or Full Panel? How to Choose Without Wasting Money
- What Are PD-L1, TMB and MSI, and Do They Affect Targeted Therapy?
- What Does 'Variant of Uncertain Significance' (VUS) Mean?
- What Happens If There Isn't Enough Tissue for Mutation Testing?
- What Is NGS (Next-Generation Sequencing) Testing in Cancer?
- What Is a Molecular Tumour Board and Why Should You Want One?
- Which Cancers Should Always Be Tested for Mutations? A Checklist
- ctDNA and MRD Testing: Tracking Cancer Through a Blood Test
Foundations & How Targeted Therapy Works
- Adjuvant and Neoadjuvant Targeted Therapy: Treatment Before or After Surgery
- Antibody-Drug Conjugates (ADCs): The Smart Bombs of Cancer Treatment
- Biosimilars and Generic Targeted Therapy Drugs: What They Are
- Can Targeted Therapy Be Combined with Chemotherapy or Radiation?
- Can Targeted Therapy Cure Cancer? An Honest Answer
- First-Line, Second-Line and Beyond: How Treatment Lines Work
- How Doctors Decide Between Chemo, Immunotherapy and Targeted Therapy
- How Does Targeted Therapy Actually Work? Explained Without Jargon
- How Long Does Targeted Therapy Take to Start Working?
- Is Targeted Therapy Painful? What the Treatment Actually Feels Like
- Is Targeted Therapy a Type of Chemotherapy? Clearing Up the Confusion
- Oral Tablets vs IV Infusion Targeted Therapy: What's the Difference?
- Precision Oncology vs Personalised Medicine: Are They the Same Thing?
- Targeted Therapy Success Rates: What the Numbers Really Mean
- Targeted Therapy for Stage 4 Cancer: What You Can Realistically Expect
- Targeted Therapy vs Chemotherapy: 12 Differences That Actually Matter
- Targeted Therapy vs Immunotherapy: Which One Is Right for You?
- The 8 Main Types of Targeted Therapy Drugs (With Examples)
- What Do Cancer Drug Endings Like -nib, -mab and -tinib Mean?
- What Is Targeted Therapy for Cancer? A Complete Patient Guide
- Which Cancers Can Be Treated with Targeted Therapy? Full List
- Why Didn't My Doctor Recommend Targeted Therapy for Me?
Mutation & Target-Specific Pages
- ALK-Positive Lung Cancer: Drugs, Response and What Comes Next
- Antiangiogenic Drugs (VEGF Inhibitors): How Starving a Tumour Works
- BCR-ABL and the Philadelphia Chromosome in CML
- BRAF V600E Mutation: Targeted Therapy Across Multiple Cancers
- BRCA vs HRD Testing: Which One Determines PARP Inhibitor Eligibility?
- BRCA1 and BRCA2 Mutations in Cancer Treatment: PARP Inhibitors
- BTK Inhibitors in CLL and Lymphoma
- CD20, CD38 and Other Antibody Targets in Blood Cancers
- CDK4/6 Inhibitors in Hormone-Positive Breast Cancer
- Co-Mutations: When You Have Two Mutations at Once
- EGFR Exon 20 Insertion: Why It's Different and Harder to Treat
- EGFR Mutation in Lung Cancer: Complete Patient Guide
- ESR1 Mutation: Why Your Hormone Therapy Stopped Working
- FGFR Alterations in Bladder and Bile Duct Cancer
- FLT3 Mutation in AML: What It Means for Your Prognosis
- HER2 Mutation in Lung and Gastric Cancer
- HER2-Low Breast Cancer: A New Category That Changes Treatment
- HER2-Positive Breast Cancer: The Full Targeted Therapy Roadmap
- IDH1 and IDH2 Mutations in Glioma, AML and Bile Duct Cancer
- KIT and PDGFRA Mutations in GIST
- KRAS G12C Mutation: The Target That Was Undruggable for 40 Years
- KRAS Mutation but Not G12C: What Are My Options?
- MET Exon 14 Skipping and MET Amplification Explained
- MSI-High and Mismatch Repair Deficiency: Testing and Treatment
- NRG1, MET, RET and Other Rare Fusions: Where to Get Tested
- NTRK Fusion: One Drug for Many Different Cancers
- Osimertinib: What to Expect, Side Effects and How Long It Works
- PALB2, ATM and Other BRCA-Like Genes: Do They Get the Same Drugs?
- PIK3CA Mutation in Breast Cancer: Alpelisib and What to Expect
- PSMA and AR-Targeted Therapy in Prostate Cancer
- RET Fusion Cancer: Lung, Thyroid and Beyond
- ROS1-Positive Cancer: A Rare Mutation with Excellent Options
- TP53 Mutation: Why There's Still No Targeted Drug for It
- Understanding Variant Allele Frequency (VAF) in Your Report
- What If My Mutation Has No Approved Drug Yet?
- mTOR Inhibitors in Cancer: Everolimus and Temsirolimus
Next step
Still not sure what applies to you?
Send your reports across and a senior medical oncologist will go through what they mean, what is known, and what the options actually are.
Common questions
Frequently asked questions
Does CML affect life expectancy if you receive treatment?
For most patients diagnosed in chronic phase, life expectancy on a modern TKI now approaches that of people without cancer — a statement that both NCCN and ESMO support. This is not a claim that applies to all cancers; it is specific to CML in chronic phase, treated early and monitored consistently. Patients diagnosed in accelerated or blast phase have a more serious outlook, which is one reason early diagnosis and regular blood testing matter so much.
How long will I need to take TKI tablets?
For most patients, TKIs are taken indefinitely — but stopping is a recognised goal, not an impossibility. Treatment-free remission is achievable for patients who sustain a deep molecular response for a defined period under close monitoring. If you stop without reaching that threshold, disease almost always returns, though it typically responds again to the same TKI. Your oncologist will tell you when and whether treatment-free remission is an option for you specifically, based on your BCR-ABL1 levels over time.
What happens if my CML stops responding to the first TKI?
Your oncologist will order kinase domain mutation testing to look for a specific resistance change in the BCR-ABL1 gene. That result guides the switch to a second- or third-generation TKI. The T315I mutation is the most important resistance mutation to identify because it requires a specific drug in response. Resistance is manageable in most cases, and a second TKI can re-establish disease control for many patients. Inadequate response at a milestone is information, not a crisis — it is exactly what monitoring is designed to catch early.
Is it safe to have children while on TKI treatment?
TKIs are not considered safe during pregnancy, and conception while on most TKIs is not recommended. This applies to both men and women, though the evidence and guidance are most detailed for women. If you are of reproductive age and want to have children, raise this with your oncologist before starting treatment rather than after. In some situations, treatment-free remission may allow a closely monitored pregnancy. This is a complex conversation your oncologist needs to lead based on your specific response level and overall disease situation.
What monitoring will I need, and how often?
BCR-ABL1 PCR blood tests are done at regular intervals — typically every three months in the first year, then less frequently once a stable deep response is established. Blood tests to monitor organ function run alongside this. The exact schedule depends on your TKI, your phase, and how your disease is responding. Monitoring appointments are where treatment decisions are made; they are not optional extras, and a missed result is a missed decision point.
Is TKI treatment for CML available at CION?
Yes. TKI monitoring, response assessment, and BCR-ABL1 PCR coordination are available at CION centres across Telangana and Andhra Pradesh. Because TKIs are oral tablets you take at home, your regular visits to CION are for blood tests, molecular monitoring, and consultation rather than drug administration. PET-CT or bone marrow assessments, when needed, are coordinated with partner imaging and pathology centres.